ADCT - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the ADC Therapeutics Second Quarter 2022 Financial Results Conference Call. My name is Gigi, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] I will now turn the call over to Amanda Hamilton, Investor Relations Manager. begin. may you Amanda,

Amanda Hamilton

ir.adctherapeutics.com opening This Camardo, quarter issued review business XXXX available website release Operator. On Releases financial Financial announcing Executive call, today's update. discuss Officer, Officer; press our Joe is Ameet at ADCT the second financial on the recent Chief call our and morning XXXX Officer; you, Press a section. we the business release This under Commercial Thank results Herron, Chief Medical before Jenn and second questions. will results quarter Mallik, Officer; highlights Jennifer Chief for Creel, Chief and

a are call subject As may statements and risks statements. uncertainties. Such conference this to contain reminder, forward-looking

for conference forward-looking this to not as unless and isolation of non-IFRS includes so obligation information and in disclaim These presentation measures in materially measures the We financial information in date statements statements, the For substitute financial concerning of as from do U.S. Securities should prepared or Today's statements you could refer X-K Such and expressed Exchange applicable also forward-looking on only statements cause by law. accordance required earlier XX.X Exhibit in with and or with forward-looking the our Statement the to these regarding update addition to measures. that report of we today. or Cautionary speak implied undertaking Form Commission limitations section to in titled statements. as additional considered factors any those non-IFRS IFRS. call to these expressly differ have actual and results a filed be

to quarter of financial in for measures contained the Ameet historical earnings pleasure is release pass reconciliations IFRS information You should definitional the call refer to to information Mallik. It my over comparable the Ameet? to now non-IFRS and measures. company's the second

Ameet Mallik

joining us you thank today. Thanks, Amanda, and for

on with months, for role in last I've plan into forward. now Before its I my take this that quarter, three the been thoughts CEO we the get to of I've speaking on intent would take capitalize and opportunity dive a maximize and of best business share three and the tremendous company the to months all science details the listening a meeting sites like into and and and spent to we for the of looking observations deliver across stakeholders. employees with determine My how tour, was to all physicians unique deep level. on and aspects investors talent the impact business our our to

one emerged joined and that reasons in the leader the promising that benefit ADCs of I to have to Therapeutics class and and of both is ADC come. of main a years First the pioneer why set is of therapies field and ADCs. patients potential for broad company have foremost, the as a a exciting

We are of launch agile of by of and well from with CMC starting our pipeline commercial. DLBCL, company and up as and value with The and that advancing extending and our been experienced hematology has to a the capabilities for tumor from fully ZYNLONTA ground the ADC and integration chain expertise integrated and validated strong the our team approval development we innovative solid clinical platform research third-line built programs. seamless as promising

advocacy growth and our to increased ZYNLONTA third-line maximize potential the for QX to amplify awareness mid continue and the in We've over the sales we and plus horizon with The we to our do three to about portfolio? near, time maximize We how net horizons. ZYNLONTA We the program, and on in DLBCL of we our and plan in million XX.X market. X% of creation and platform will Starting So long-term. plan messaging. potential to delivered execute think the and deliver continue representing patients hematology will value near-term QX.

tremendous We capture our differentiated to product to and are the in we and both academic community. believe and depth this in remains growth. have profile ability With in setting ZYNLONTA's steadily our increase fine-tuned opportunity approach breadth the we confident

working our are lines and QX, trial we also earlier rituximab. therapies. to combination X ZYNLONTA combination move Phase continue to confirmatory in In with in into We LOTIS-X enroll

and ZYNLONTA serves ZYNLONTA also double unmet sizable medical and additional the novel combinations need unfit LOTIS-X population in an trial opportunity. population within setting. offers We the The initiated LOTIS-X the a the trial addressable patients. trial patient LOTIS-X expansion and combinations rituximab and LOTIS-X The first-line for of clear in frontline frail current and

the Overland have ADCT we reach expand strong of China in in Japan. three partners have In the our to Tanabe globally. we and Greater Beyond ZYNLONTA now Asia, strategic U.S., with collaborations Mitsubishi

more agreement Sobi signed need. the in patients widely focus with territories partner on making even experienced ZYNLONTA commercialization in all also recently while ZYNLONTA other will development and in an for to in the open which Europe committed and U.S., commercially an available more We allow to worldwide us executing of

pivotal Cami program ADC second-hand released June. the the same lymphoma Hodgkin PBD at based for based Phase Our Hodgkin We and an in from EHA and is data trial X presentation lymphoma validated platform. line top on oral

stability complete meeting results pre-BLA the second next to has our of on year, time regulatory we been scheduled based FDA with the for and manufacturing the of for mature. that the we data plan half submission need meeting, Our September given to in

scientific have preclinical where advance we the three toolbox in to opportunity rationale of clinically in and to to the clinic long-term our solid The by a all validated provides horizon heading upon proprietary are of novel technology promising These two IND build we and towards pipeline, horizon the our leveraging new targets, mid-term directions. include our and different expertise supported in five data. development which mix programs, are filing. and tumor Moving ADC strong

constructs the of on partnering broader expand the and payload, We new to platform. are working assets our realize well and full as next-generation antibody approaches incorporating toolbox as value ADC

now the to allow on execute to we pleased and have strategy signing our our the objectives. a runway XXXX. deliver will of early With into are cash time us agreement, on extending the This Sobi

will aim all accelerate to to those We supported science, and on are ultimately We will growth and commercial which promising strong capital approach terminate tolerate and opportunity. disciplined company a creation value programs allocation of that for and identify not the by unmet take need based stakeholders. the data, medical

the we many after We and to team. having drive Jennifer you are about launch. Jennifer? forward call common the the cancer to by progress. like turn and privilege on on the employees the to to our Finally, struck talent, opportunities sites, to meet look impressed ahead. all now updated of visit I our our over and by help would purpose, capabilities to patients, keeping energized I'm of ZYNLONTA at the I'm report

Jennifer Herron

the progressed everyone. you, Thank our steady month-over-month quarter. ZYNLONTA we growth good share and as morning net million, launch Ameet, am in QX, were an ZYNLONTA QX. demand representing X% QX. $XX.X update in pleased on through sales to growth With I versus the

a a launch, challenging Just a we environment. progress the over year little solid into have made in

many for market. line the However, plus third there are in DLBCL growth opportunities more

of coming launch, We academic in centers. drive profile we have and plan we have the to with majority Since we the differentiated the in focused growth that a place will our remain the quarters. ZYNLONTA capture steady opportunity confident focused product on efforts that

advocacy and of influencers built leaders for with these at specialists entire thought across institution team have market. We the

plus two the setting three to compared to patients third-line community in respective patients on counterparts. DLBCL see more academic-based number clinicians are community average, of times the as DLBCL their there Although

in to solid have educating academic foundation engaging accounts. XX% to lymphoma accounts. progress advocacy across good and breadth for approximately this academic depth from doctors awareness We country coming convert made With of continue see and growth opportunities good place, increased and we volume key building with the as in our we

the initial opportunity setting during is the While where in academic patient the majority population it third-line period, is plus made to on broader treated. launch strategic sense the focus DLBCL of centers the community

increase place, we in permanent and intensifying adoption With are awareness to the in J-code our centers. these efforts now

are We significant importantly versatility manageable with Factors to as and our in that the product side will efficacy, of practice rapid confident effect community. well administration such agent respond, patient-friendly patients single and ZYNLONTA's profile, physicians resonate and profile differentiated the schedule. time

significant ZYNLONTA and plan the market. for areas second we this half capture focused experience, have have the of advocacy that and three we drive in We execution. plan the opportunities to identified For to awareness, year, a remain

provider opportunities are community we in-person on team are health pass local increasing the our market level, setting. academic optimizing care and First, execution our the regional including centers as customer-facing the congresses. broader deeper at share and help of both of us all in and will This

several to increasing the through into as important embedded with QX are XX% often visits access being quarter. ZYNLONTA seen practice. we have of total interactions trend we with is to providers expand face the as encouraged to products know it we takes as for that care new our We approximately exited such This face health be

oncology Next, we key with partnering network. are community

make network We are the broadening to differentiated profile sure the of the our market. physicians educational efforts within understand

also opportunity. We the the proper ensure paradigm may in that patient ZYNLONTA to for positioning DLBCL has every want treatment from of benefit ZYNLONTA the who

level. options can choosing active the treatment discussing and We patient the play on in recognize patients Finally, caregivers role their with and physician. their

us advocacy our newly regional established the our patient-friendly the well efforts a community has ZYNLONTA launch, A to patient on. intensifying build the our and profile. through team grassroots as educate year product level good launched build little to are for foundation as to at local over mobilizing We marketing a DLBCL about campaign into cross-functional

Now, areas. we will work into untapped expand to

over We coming a earlier will standard-of-care as have as DLBCL and remain continue focused a sales grow we a lines confident over of ZYNLONTA of plan quarters the establish ZYNLONTA to and place treatment. see to we third-line cornerstone ZYNLONTA in time

over turn pipeline. I provide our to Now update an Joe will to call Joe? on the

Joe Camardo

I'm an trials. you, on happy our clinical provide update Thank to Jennifer.

be progress enhanced good trial, explore and in occurs. other are to ZYNLONTA polatuzumab. combination drugs This with During unfit rituximab novel trial reduced frail. we Phase earlier need to lymphoma Other has The of you on often unmet patient who LOTIS-X. with and am we this study Phase study patients unable are combinations the a enrolled starting combination clinical about shown we LOTIS-X to newer the doses. the We to as R-CHOP I first will potential potential into of trial it regimen into frontline DLBCL excited ZYNLONTA keep trials. or even significant activity In first-line at development initiated with will These the ZYNLONTA quarter, novel tolerate ZYNLONTA will evaluate with in updated move our in in focus clinical particularly are combinations the preclinical with July, to to excluded rituximab patients studies. this from lines this of our X treatment. investigate added as who a the Xb patients address made combination the programs in the

to open interest initiative and more treatment our decided And this To in patients. targeted lymphoma the ZYNLONTA from have LOTIS-X States. so market. on in received younger comparator the removed being physicians in they several lag high on from sites U.S. and feedback activated we've of of to terminate trial We've degree United behind advances due positive the the we this execute ideally, to relapsed-refractory strategy, follicular should and

the combinations we opportunities program, continue novel we explore for discontinued with While have monotherapy lymphoma. for ZYNLONTA will to follicular

a an patients to the enroll registration single Biopharma trial sharing clinical ahead their are part LOTIS-X, you our for to first of by second update EMA eligible by ex-U.S. regulatory ADCT for bridging Phase and into agent we trial. registration line has decision supported was study patient activities who In the of completed the the from In major the quarter rituximab on part X with moving the in not in China partnerships, continue Japan. to in schedule forward venture the these of study we the China XXXX. the the completed with Expansion the safety quarter forward Overland cell To Phase development transplant. are and in combination X global randomized the running which enrollment Tanabe, DLBCL stem in joint we ZYNLONTA we partnership with receive on of and first and medical Mitsubishi meeting. patients results give an first also plan in dose of confirmatory look track upcoming was of LOTIS-X randomized are in Finally,

our on updated keeping focused execution successful the to on ZYNLONTA are and we forward of We the you look progress. trials,

six Congress to the study Turning XX%, of presentation prior with responders of a released overall in lines oral Cami, from response duration rate was of XX% at of rate EHA This data complete treatment. and response response months XX.X for at of of median follow-up in lymphoma, a showed you presentation now when Hodgkin Phase the an X in an the patients all June.

represent that and for the well significant call we benefit told progressed included for data patients and the patients disease these over use treatments the have other progressive a study, pembrolizumab half transplant. despite were have in of as brentuximab advisors stem Our cell these both us as

We pre-BLA and will the of in data. we by scheduled and timing in stability September, regulatory availability the maturity is a FDA of XXXX. have submission meeting with complete the driven manufacturing The second the a half

move Before an update from I like hematology, on would to provide on we ADCT-XXX.

may patients continue ADCT-XXX optimize the to with signs activity of conjugate work in We evaluated recall schedule. antibody-drug leukemia. acute dosing MD This or being in Phase You refractory X/X an CD-XX. targeting is a early Anderson relapsed and clinical with is trial lymphoblastic to see

We will in you update future. the

tumor solid our Now moving to on portfolio.

dose a tolerability a expect as as to trial Xb we determined From the stage. dose with Cami data ongoing study the expansion and in escalation will the any activity safety have perspective, been we we complete well the anti-tumor combination of the the escalation timing on combination, dose enter safety next optimum and year. When signal efficacy have of pembrolizumab. has and First, Phase

We ADCT-XXX trial X are targeting proceeding KAAGX. the Phase of with

as expect escalate continue tolerability, safety the XXXX. have signals well and of indication anti-tumor dose to in an We as of to activity early and

now with with Moving study gene combination in on includes the and patients actual patients AXL, patient sarcoma. trial. and targeting in with monotherapy dosed arm first Phase amplification been the in to a has arm ADCT-XXX a gemcitabine Xb The enrolled

antibody-drug give will metastatic enabling IND preclinical in on targets plan a advanced conjugate is project to completing malignancies. DLKX in tumor two National into is we generation in update. cancer. to I the validated prostate over our call the optimized Jenn turn collaboration With solid for both PBD-based This We that year. assets financial the are with ADCT-XXX ADCT-XXX work programs. Finally, targeting a Institute. next neuroendocrine to PSMA, clinic Cancer of take targets these second

Jenn Creel

Thank and you, good everyone. morning Joe,

$XXX in As we of Based million, include we $XXX does July XX, milestones and our from million from equivalents balance the have of upfront as Sobi and March of payment cash received of million and year. approval agreement to of Potential from The on cash June due of expected runway compared now our Sobi extends include cash that early had cash upon Royalty XX, near XXXX. business not plan payments $XX regulatory the DLBCL as Healthcare term and potential the agreements milestone Sobi of we EU first Partners, third-line milestone a into million XXXX. from commercial ZYNLONTA Royalty sale. have Partners these from the for and $XX European $XX million this Healthcare

release of P&L to $XX.X for reported quarter earlier were sales million as today, net $X.X issued was in Turning sales the Cost the XXXX. press the we product second for ZYNLONTA million Company's not the with quarter that primarily quarter of within The compared for manufacturing to related to the the same antibodies associated $X.X we're increase specifications. was the impairment million in XXXX. charges

the compared second XXXX same sales based in FDA upon the due $XX to of as second due same activity for quarter impairment period R&D the due XXXX to expense a ZYNLONTA to quarter product May in $XX million the quarter. of to million the R&D cost sales in of $X.X of the expenses compared quarter of quarter commencement for that for of second previously during charges addition, reversal full XXXX, sales quarter ZYNLONTA during recorded XXXX million XXXX. In increased the to the XXXX. were approval increased

for for same for for the compared for same share-based ZYNLONTA quarter were to XXXX quarter selling $XX and in quarter loss in to G&A loss million invest earlier G&A $XX of ongoing as was decreased efforts. to in we ZYNLONTA the of portfolio. same and The compared $XX same $XX marketing quarter a XXXX. expense. XXXX In quarter the and XXXX net the due reflects $XX compared lower treatment compared the for the our quarter second compensation million expenses increase launch $XX for expenses primarily quarter broad XXXX. second and the for continue million the in million the second to lines Net XXXX. the the Selling quarter marketing million expenses quarter to million trials expenses were to addition, commercial for

the product a and same per the due as product net to the diluted sales, compared The marketing loss and partially primarily was XXXX was expenses. net revenue, to decrease Our ended share quarter quarter in of offset $X.XX the second period by June compared $X.XX the in loss for R&D, in net XXXX. quarter XX, loss higher same increase cost to for selling in XXXX of

net share quarter for second the turn Agreement, net result quarter that deferred today of Healthcare quarter in interest to the release loss, that income partially I XXXX. in arising million XXXX the remarks. was net the was Deerfield by our XXXX. Adjusted expense Ameet? offset Facility the certain of loss fair Royalty value $XX quarter associated derivatives second adjusted an loss compared for for as million measure $XX as call quarter addition, With in earlier press the for decreased with of second same items described net will loss excludes changes the with In $X.XX Adjusted per $X.XX closing higher to of Partners. of issued in a a the per associated from net with back the loss Ameet an obligation same to compared adjusted share

Ameet Mallik

and driving our therapy, to hematological ADC advancing earlier includes the in forward. ZYNLONTA on and tumor lines areas well achieve focused going of Joe pipeline solid the ZYNLONTA working of differentiated expanding and executing our to platform. programs our positioned of key and are Jenn. remain Jennifer, develop you, all we Thank we objectives This on launch, To business conclude,

Now questions. available the team will be Operator? for

Operator

you. Thank

the We begin question-and-answer will Jefferies. comes of question Shi Our the session. [Operator Instructions] now from line first from Kelly

Kelly Shi

my Thanks for taking questions.

submission data submission BLA the by to if And next the curious manufacturing Thank for the I and stability the lymphoma follow-up. of FDA. data also anticipate I'm which of clinical second would in Cami toxicity [AdCom] half sure. targeted you have Hodgkin GBS good-shape So you. also requested in not mentioned package you patients, for year, in

Ameet Mallik

question. to you on this to for I'm the going Joe thank to Yes, answer. pass

Joe Camardo

that's and rates the Sure. Yes. condition. The the good efficacy I data from packages and very side. clinical in very response duration the positive mentioned all

in last you been able Syndrome, interventions the On to Guillain-Barre very sure only we side, some the AdCom. will is -- that GBS develop make treated. for about it's the eight we predict early have safety an mentioned We have part will positive straightforward of to safety and diagnosed last of be for is cases -- believe was study LOTIS-X. I'm it. thinking we cases there benefit impossible balance AdCom. the and and any the package that of don't efficacy of Cami. and have was not have sorry, our be is We now prepared -- can and we addressed. We advisors don't that but X that Phase be is, and the any FDA are activity, very late I'm the clear The to an there the safety question so If

Kelly Shi

-- a I Great, have thanks. And also

Ameet Mallik

Thank you.

Kelly Shi

question sales. Thank you. on have And also I ZYNLONTA a

sales curious ADCT in the in a reported clue guidance could in the J-code about sales ramp-up in the to number the quarter also how get factors sales to for could could and we we some start signal going to the and impacting but whole half quarter strong since I'm CAR-T offered Thanks. second showed to sales to for April -- year. revenue now has X. the terms first lymphoma increase those a XXXX, QX So be QX effective patients from think and extended and ZYNLONTA of line be second this

Ameet Mallik

about address I question, Yes. manufacturing turn previous you before Thanks, stability. the more one to Jennifer over also Kelly. to And it I which your want asked is, thing in

a with clinical good the clear, in of matter stability, just manufacturing moving is packages that The said be meeting the Joe have planned time. we just in shape So and September. to FDA a

question waiting manufacturing timing that that's now, going and for So of year. when drive what's half the to next filing data of we're over batches the completion second the stability were I'll on planned just in turn the to Jennifer. mature the it ZYNLONTA But for to produced, the

Jennifer Herron

Yes, Kelly, question. thanks for your

seen setting. in specific increased regard was CAR-T second So utilization question line in CAR-T, your with to the we have

was had partnering really community We treating only influence our community our to those got as April, in J-code from I've thought level leadership and permanent the in takes We prescribing lot year the There paradigm, and a with second so exited ZYNLONTA. CAR-T of in we're is post marketplace. you a in of opportunities have face-to-face importantly demand true is access this we month-over-month person, in but trials about growth increasing centers, we about engagements if the the in in depth academic academia. oncology embedding opportunity. product the really now national converting because three the We've specifically our awareness did away of we are this not started more quarters as been the awareness of encouraged, which also and and advocates an for XX% and are the on through we that us seeing we and ahead we definitely of across to realize we regional use mentioned initiatives opportunity QX, and the the portray the prescribing ZYNLONTA. academic important as tremendous out differentiated of move focusing see half really that barrier in to physicians think ZYNLONTA quarter and down was think to year J-code, coming academic with centers profile we of growth on the still And opportunities and it for mentioned centers developing good have doubling volume and

Kelly Shi

you. thank Great,

Operator

you. Thank

from Our line Gregory Renza RBC. next the question of comes from

Gregory Renza

to out just the from just tour taking to for Hi, past is one more good just few feedback and listening laying hear morning, the higher the and your goals? Maybe helpful Ameet months over team. my is medium about even curious just you thanks what how facing. and thinking out in longer you, level with questions. unique hear your term you're and I'm time in time the if for that Congrats think ADC is you any and all near allocating progress on positive helpful at across to about the anything there respect certainly particular particular challenges jumping those just this that's horizons? environment are And

Ameet Mallik

Jennifer no team one spent the of look, field on Yes, it's thank and it. great in get challenge with the with I because for think clear and when always a lot question much you I so with was you a customers, pretty the that insight asking Yes lot I've to Joe's me particular a and - think of ground. meet best employees time

You you when with of get of with our meet and and customers time that's investors how lot and spend we meet a first just lot a few insights like months. my

I awareness challenging one big equally period improve during product, which COVID Jennifer institutions we it's barrier QX. the were have and a launch a - to it because provides particularly a that environment is we in awareness saw and key the because now this shut pretty for really access would established was in down mentioned, the I this still while in community is really relatively challenge as low, that say J-code think is So, is ZYNLONTA, where with of relatively thing prescribing opportunity unaided

initial we the to - only in getting that not and activity lot of indicators the hadn't had of a part customers activity at first we're the of look - calls launch. I when So

as of a would comes to at I much has me, it is. in pipeline what QX. for as going is least now mid-term - an When of the I the as three things in our it challenge, So say general, see and indicators and good just forward, those been early sort opportunity key

disciplined on things portfolio have really want and a of a prioritization to sure lot We I pipeline going our in terms activity make of of and our that portfolio what lot and of management. in of we're

Because - the in of and of are stage of going robust we to our gaining we're we've set move can process we're said decisions the development. more there research implementing in the of judges the in process to investment really terms gain IND all into I a terms decisions decisions the I and clinical these robustness stage portfolio in is clinical stages So think at do to later and that move into implemented, , criteria. how key manage

the And opportunity so putting and don't the will started want we is also because because things. a the with keep things, bear see of of things there just data team money doesn't we decisions not stop standpoint, after you to we from business

to strong I to on picked pipeline, they again we lines say terms that that's to opportunity horizon, linker to well. expand - targets, well. around technology - expand of can and past, want toolbox. we've because more ones payloads, in the we finally there's in But do that targets more biological that's they we our we fit we expand linker deals on number particularly conjugation front, been number in I in that to more then pipeline, the a of the little for really have where We've been a an up fit in number there technology particularly in really we payloads strong And payloads Difficulty] up number be done we've that we for can picked really [Technical say open of that I'd the terms big of our a But technology, want area even very that as bit ones continue the focus come. in antibody for as, want to construction chemistries. particularly that technology, the think go PBD-focused our third a for after, done So to are we things our but the possibilities, me. toolbox and would of our and some open targets lead of to and we've going think limited really, ADC space, different a the payload I PBD are

areas for still initial focusing opportunity on those take going just of to the So is, my and forward. there are where we're thoughts company where

Gregory Renza

thank there? just ZYNLONTA on sense so That's And it, now, just could that you how a missed follow-up again. of what predictability of in And quick it the case inventory to comment year now the that from really much. you a we comes XQ you thinking when have inventory ZYNLONTA. are also maybe impact do the launches on over quarters, about I one build the helpful, if the just quarters better Thanks

Jennifer Herron

Yes, I'll that take question.

inventory $XX.X we're real of reflects terms I in there. not inventory time. of of future at million, comment on for any time So really aware sales patient we significant QX, trend the this And net demand believe can't that build and

Gregory Renza

thanks it, Got again.

Ameet Mallik

Yes. very much. you Thank

Operator

Thank you.

question next comes the from Peaker line from Boris Our Cowen. of

Boris Peaker

sticking is, first Can rough maybe discussion. characteristic ZYNLONTA these a patient My ZYNLONTA give adopters? of of kind initials question you with us with

Jennifer Herron

question. Certainly Boris the and for thanks

as off So strategy, by started national thought we the academic and in leaders developed reside we and many our regional launch our and they times design centers.

There have be a our and effect product a opportunities physicians in including the CAR-T. not for strong setting. pursue we efficacy, CAR-T profile post And choose CAR-T then see think the patients reasons it the administration. ZYNLONTA setting. business spectrum are And treatment dynamic those the from the in very thought in CAR-T so unsuitable from we profile, in very of time or response, would fairly I we've support rapid believe the a and of the are to heard that to prioritized of lot marketplace seen the academic post as differentiate entire and leaders why side benefit to patients centers, with across And we've for our indication, are this variety convenient that both the manageable utilization not patient eligible

Boris Peaker

And shaping that's more well topic, on competitive of patients, how talked therapy lines about you and moving CAR-T. Can and and we second you DLBCL obviously several ZYNLONTA landscape helping but specifically? earlier up CAR-Ts those and to there's fitting there is do see drugs that where is third-line known that's in comment outside that competing in

Jennifer Herron

ZYNLONTA don't positioning changed of positioning our I outlook versus Boris. the our - Yes that launch - for has positioning. think

LOTIS-X Recall with LOTIS-X into the product fact those getting are and patients. in and trial The type experience response. differentiated heavily the So ZYNLONTA. seeing to world physicians it of setting rapid profile comes the have of of a time the down really are these - response to the that pre-treated robustness real patients

compete where opening continues to bit all, have a from putting standpoint of is more really optimizing access because customer really effort the a we're we think profile up. opportunity with so, little that I And a ZYNLONTA facing well execution of teams unique - our

where of putting And in we our centers still Ameet the opportunity of both and the that's a academic focus. community, mentioned, have ahead bit in and we're us so as

Boris Peaker

Great, thanks question. taking much for very my

Operator

Thank you.

next Harrison comes Stanley. question line Morgan from from Matthew the of Our

Unidentified Analyst

This is [Chris Hughes] speaking for Matthew.

two have the regarding first is we So ZYNLONTA. questions, question

setting QX? whether wondering, in community you patients Just the any in getting are

Jennifer Herron

the getting we community Yes, patients are in setting.

achieved the of that As in J-code through I centers. mentioned some came community the do to raise level barrier takes in the work in academic I we've the of beginning to a April, still that awareness permanent have and J-code, prescribing, while the to think away the we really

our volume the is of XX% about academic the conversely coming and from community. of is the so centers volume XX% from so, coming And

not us is opportunity community real networks. also J-code, I think for forward the full execution the the only oncology with moving of but the partnering

Ameet Mallik

academic. fewer doctors for and far adoption average all the mentioned have as Jennifer Jennifer lines because just so have adoption general you call had Partly, typically seat said and a like this of the that would slower new to the than DLBCL, earnings in patients add community field I during you tend in what Yes, slower later community adoption to in the therapies.

fact our I profile think opportunity a have of for we that efficacy fast the are easy a response, manageable weeks. XXX-minute gets physicians, infusion many fact to to real understood I the profile, safety effect really the side it's it's that Jennifer strong profile fact that agent, the reasons that that - three or very think is known the every mentioned. The as by more molecule also time single fact we administer,

So to administer. it's really easy

takes fit to QX. there's - predicted, of think as community. to in in see and get going think now Jennifer why that have it's and we'll you'll well the the But adoption start team I longer get believe and a adoption later I - So happening we to it lot reasons

Unidentified Analyst

lymphoma. second is my in question follicular And ZYNLONTA helpful. regarding very That's

and your LOTIS-X and You terminated what's with is from FDA mentioned that Lonca path do you the feedback get the any lymphoma? follicular forward in

Ameet Mallik

Yes.

want Joe, take that? So you do

Joe Camardo

where not rescue line public said it from future the look question. recent of some of the agents remission treatment thanks remains single late much from boards get the FDA's but as like information specific Yes, We and as lymphoma, their chance clear did the a long-term the and more was sort that. Sure. The for a FDA, don't a FDA very actually follicular in advisory statements, that an earlier of for possibility. option, interested

the follicular time that to and So we consideration moderate to lines but so to earlier our more would into for future combination take way and that a I lymphoma. for promising change get much of we're doing some and looks look it's us data, say, and data took that in of at focus some going that, like dealing with program

Unidentified Analyst

you. Thank

Joe Camardo

welcome. You're

Operator

you. Thank

question from from comes next [indiscernible] Our the BofA. line of

Unidentified Analyst

for questions. you taking my Thank

the sense Just months. think of data catalysts XX be wanted over your what you will to next the get

the With we second then in expect of should the programs. conferences on for And the any half presentations Lonca. of lastly oncology of launch slope from year, the the your ongoing any upcoming

Thanks. what doctors well simply need had you how awareness? for trying doctors today, If might just a prescribing limited in it comfortable benefits appreciate they today the the drug. ask I'm would of understand feel you it of patient view pool, as to just to it's is doctors matter said your Or community-based to

Ameet Mallik

Yes.

it's let's question the I milestones, XX So the highlight to adoption. milestones. Yes, take answer over to the say maybe to safety upcoming of this going it year. meetings. lead-in medical LOTIS-X didn't rituximab to the will be second one, but XX months an in presenting from which be to with the half the the announce on around Jennifer question We a -- And we're ZYNLONTA said going study I'll ZYNLONTA over turn combination past the upcoming ask year next, from few I'd it at just data different to I'm

to regulatory the from next a We get of with also year EMA our European decision around by Cami. approval expect QX

We the path given in year, And half escalation stability of to that upcoming complete September the it this next forward. clarity in process we submission mentioned, will as have to We're plan some initial think with we initial of the meeting as not important from the will of really we're year. and both we which being we us that we safety in programs have data still of specific on have the to mature, timing then With a an signs pre-BLA next for of and meeting expect the in year. XXXX. for in but give efficacy be those of dose KAAGX, data more expect results both Cami programs second

highlight you key ZYNLONTA. milestones And So next I those about XX over to would are, XX I'll months. I'd the Jennifer turn that to talk say the it to

Jennifer Herron

[indiscernible] thanks year question. less has pretty been for needed opportunities product for the face-to-face educational This with interactions or challenging a new past really that's lot a introduction.

more we're though We a lot really through seeing up that are hopefully as interactions. encouraged and QX, And face-to-face opening it's we good. for move

the to third do as an industry list the face-to-face trial a we to over a mentioned patients. paradigm with well the time. initial earlier interactions mentioned, quite line where regard ZYNLONTA doing community, related good those centers which have competitors half at is product represents awareness team of and treatment job we you in quite trial, norms to the embed We I done with fairly all advocates have need opportunities DLBCL this few In plus convert as there. in academic Our and versus even

significant a opportunity. So

that standard-of-care. I experience with and raise in with now the third-line ZYNLONTA opportunity embed positive permanent there community think the as a to J-code ZYNLONTA place, have well the awareness really to get initial we in

this and to from of a year think But the challenge the encouraged continues I So that I'm what seeing to I'm launch. been be receptivity the first strong. very profile for access has

Ameet Mallik

[indiscernible] to said. hematology to academic adopt community in add on what just I products mean And physicians. tends oncology than to Yes. Jennifer the slower new anyways

case, the lack think of things, heightened probably access. this I two it by in was is one

community months. many thing into And of the community, of is patients just So where ours patient a doctor the then a ZYNLONTA four therapies, seeing about is a to launch. particularly the every maybe which lack nature this year new diffuse just second knowledge three

also urgency our fits about setting. not frequency untapped I getting drives that particularly well access. I therapy, in think learn that new the the So remains and if opportunity especially But think profile big to that you're

access terms in And I bigger the product. of right given now opportunity in that Jennifer that's as I phase physicians spoke for right So the about, think that near of we're in the early number much growth the knowledge of some picks and launch had now that community mid-term. interactions in the the the think up, for the

Unidentified Analyst

is now? sorry I for split between docs if color. thanks community it, have you've this Okay, missed And already right that I'm if might and what said your academics

Jennifer Herron

Ye.

So our in volume XX% academia. volume, have of still about terms of we coming from

as future. of fuel will it in acquisition is the Ameet lot the come. steady to ordering, But see ordering accounts, time, there our opportunity do split, terms a terms more growth to In that that a take but of in account community we it's XX-XX mentioned, in it's going

Unidentified Analyst

have you? don't on constraints do And you now, Okay. any right supplier

Jennifer Herron

with supply issues that commercial no are regard of. There to I'm aware

Unidentified Analyst

you. Thank great. Okay,

Operator

Ameet conference for would to remarks. you. like Thank to Mallik over turn now I back the closing

Ameet Mallik

all our keeping you forward Thank to And to updated of Thanks your very progress today. you support I ADC joining call much Yes. nice continued our have hope thank look Therapeutics. of Thank you. for you a for on you. you and that day. We

Operator

conference call. concludes you This disconnect. may for Thank now participating, today's you

ADC Therapeutics (ADCT) 9 Aug 222022 Q2 Earnings call transcript